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Abstract
Aims/hypothesis This study aimed to evaluate the preva-
lence of retinopathy in long-surviving type 1 diabetic
patients. It also investigated the 25 year incidence of
proliferative retinopathy and associated risk factors in a
Danish population-based cohort.
Methods A population-based cohort of 727 type 1 diabetic
patients from Fyn County, Denmark, was identified in
1973. In 1981–1982, baseline retinopathy was graded and
other risk factors were assessed in 573 patients. Twenty-
five years later, 308 patients were still alive. Of these, 201
(65.3%) were re-examined at follow-up in 2007–2008.
Results The median age and duration of diabetes at follow-
up were 58.8 and 43 years, respectively. At follow-up, the
prevalence of diabetic retinopathy was 97.0%. Non-
proliferative retinopathy was found in 45.8%, and 51.2%
had proliferative retinopathy. The 25 year incidence of
proliferative retinopathy was 42.9% among patients at risk.
In a multivariate analysis, baseline HbA1 (OR 2.14 per 1%
increase, 95% CI 1.06–4.31) and non-proliferative retinop-
athy (OR 4.61, 95% CI 1.94–11.0) were the only risk
factors for incident proliferative retinopathy. The long-term
incidence of proliferative retinopathy was not associated
with baseline duration of diabetes, proteinuria, smoking,
body mass index, maculopathy or systolic or diastolic blood
pressure.
Conclusions/interpretation Retinopathy among long-
surviving type 1 diabetic patients is almost universal.
Proliferative retinopathy was found in half of these patients.
In addition, the 25 year incidence of proliferative retino-
pathy was high. Baseline glycaemic regulation and non-
proliferative retinopathy were identified as risk factors for
incident proliferative retinopathy.
Keywords Diabetic retinopathy . Glycaemic regulation .
Non-proliferative diabetic retinopathy . Proliferative diabetic
retinopathy . Risk factors . Type 1 diabetes
Abbreviations
ETDRS Early Treatment Diabetic Retinopathy Study
WESDR Wisconsin Epidemiologic Study of Diabetic
Retinopathy
Introduction
Diabetic retinopathy is the most common complication of
type 1 diabetes [1–3] as well as the leading cause of
blindness in the working-age population of the western
world [3, 4]. As part of the Wisconsin Epidemiologic Study
of Diabetic Retinopathy (WESDR), the 25 year progression
of diabetic retinopathy was evaluated in a recent paper by
Klein and co-workers [5]. The progression of diabetic
retinopathy and the related risk factors were evaluated in a
population-based cohort of 955 type 1 diabetic patients.
Progression of diabetic retinopathy and progression to
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proliferative diabetic retinopathy were found in 83% and
42%, respectively. Risk factors for incident proliferative
retinopathy were poor glycaemic regulation, high systolic
blood pressure, proteinuria and higher body mass index.
For instance, the 25 year risk of proliferative retinopathy
increased by 38% for each 1% increase in baseline HbA1.
European results comparable with those obtained from
the American WESDR are lacking. Consequently, the aim
of this study was to estimate the prevalence of diabetic
retinopathy as well as the 25 year incidence of and
associated risk factors for proliferative retinopathy in a
population-based cohort of Danish type 1 diabetic patients.
Methods
Cohort and baseline examination As previously described
[6, 7], all type 1 diabetic patients from Fyn County,
Denmark, with diabetes onset before the age of 30 years
(n=727) were identified based on insulin prescription as of
1 July 1973. In 1973 Fyn County had approximately
450,000 inhabitants and was considered a representative
9% sample of the Danish population [7]. In 1981–1982,
577 of 627 surviving patients (92.0%) participated in a
clinical baseline examination. Data were later lost on four
patients, leaving baseline data available for 573 patients
(Fig. 1). All patients gave a written informed consent at
baseline as well as at the follow-up examination.
At the baseline examination, patients underwent a
structured interview and ophthalmological and clinical
examinations were performed [6]. BMI was calculated,
and blood pressure was measured using an Erkameter
Sphygmomanometer (Morton Medical, London, UK) on
one arm with the patient in sitting position after 10 min of
rest. Blood measurements included HbA1c as total HbA1
(normal upper limit 8.1%) with resin 70 (Bio-Rad,
Hercules, CA, USA) at 20°C and pH 6.7. Proteinuria was
considered present if more than or equal to 0.5 g/l protein
was found in a spot urine sample taken at any time during
the day. The smoking habits of the patients were noted.
Current and ex-smokers were considered to be smokers for
the models.
Using tropicamide 1% (vol.vol.), both pupils were
dilated and a slit-lamp examination performed (Haag-Streit,
Wedel, Germany). Ophthalmoscopy was performed and
retinopathy was described and classified by a single trained
observer. The patient’s level of retinopathy was determined
by the worst eye and classed as non-proliferative diabetic
retinopathy or proliferative retinopathy, if present. Non-
proliferative retinopathy included microaneurysms, hae-
morrhages, hard exudates, cotton-wool spots, venous
beading or intraretinal microvascular abnormalities in the
retina. Proliferative diabetic retinopathy was defined as
newly formed vessels in addition to the above. Further-
more, the presence of photocoagulation scars from pan-
retinal treatment was graded as proliferative retinopathy.
Maculopathy was defined as a retinal thickening in the
macular area and/or the presence of perifoveal hard
exudates.
Follow-up examination The follow-up examinations took
place between 1 March 2007 and 1 March 2008. A full
medical history was obtained. Blood pressure was mea-
sured on one arm in sitting position after 10 min of rest. An
Omron M4 (Omron, Matsusaka, Japan) was used and the
mean value of the last two of three measurements was used.
A history of smoking was obtained. Measurement of HbA1c
was performed by cation exchange chromatography using
Tosoh G8 HPLC equipment (Medinor, Broendby, Den-
mark) with reagents as recommended by the supplier.
Normal upper limit of HbA1c was 6.3%. Nephropathy was
evaluated in a single spot urine sample taken at any time
during the day. Definitions were: normoalbuminuria
0–19 mg/l, microalbuminuria 20–200 mg/l and macro-
albuminuria 201 mg/l and above. A monofilament test
(Bailey Instruments, Manchester, UK) was used to test for
neuropathy. Data on macrovascular disease were obtained
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Participated at baseline 
(1981–1982) 
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Data lost 
n=4 
Non-responders 
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Dead/emigrated 
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Data available 
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Non-participants at 
follow-up 
n=87 
Dead (1981–2006) 
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Alive (2006) 
n=308 
Not available 
n=0 
Participants at follow-
up (2007–2008) 
n=201 
Fig. 1 Numbers of patients for whom data were available at different
stages of the study
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from the Danish National Patient Registry and defined as
follows: a history of stroke, myocardial infarction, angina
pectoris, percutaneous coronary intervention, coronary
bypass surgery or limb amputation.
Pupils were dilated and fundus photographs were taken
in both eyes. Nine 45° colour fields were captured with
Topcon TRC-NW6S (Topcon, Tokyo, Japan) and auto-
mosaicked with IMAGEnet. Photos were graded using
grading protocols [5, 8, 9] according to the Early Treatment
Diabetic Retinopathy Study (ETDRS) adaptation of the
modified Airlie House classification of diabetic retinopathy
[10, 11].
ETDRS levels were as follows: 10, no retinopathy;
20–37, mild retinopathy (microaneurysms alone or with
hard exudates, cotton-wool spots and/or retinal haemor-
rhages); 43–47, moderate non-proliferative retinopathy
(microaneurysms and intraretinal microvascular abnormal-
ities, moderate/severe retinal haemorrhages or venous
beading); 60–71, proliferative retinopathy or scars of
photocoagulation; 85, end-stage proliferative retinopathy
(macula obscured by haemorrhage, retinal detachment at
centre of macula, phthisis bulbi or enucleation secondary to
complications of diabetic retinopathy). The final category
was determined by the score for the worst eye.
All images were graded at the Ocular Epidemiology
Reading Center, Madison, WI, USA. Inter- and intra-
observer variations and the validity of the systems have
been presented elsewhere [8–10, 12].
Statistical analyses Continuous data are presented as means
with standard deviations, and categorical data are presented
as percentages. All statistical differences were tested at the
0.05 level. Confidence intervals that did not cross 1.0 were
considered statistically significant. For categorical data, χ2
tests were used; for continuous data the Mann–Whitney and
Kruskal–Wallis tests were used to test for differences
between two and several groups, respectively.
Logistic regression analyses were performed to calculate
ORs for incident proliferative retinopathy between baseline
and follow-up. All patients without proliferative retinopathy
at baseline who participated at follow-up were considered at
risk. ORs were evaluated in an age- and sex-adjusted model
as well as a multivariate model. Stata Intercooled 9.2 was
used for all analyses.
Results
Of the 573 patients who participated at baseline in 1981–
1982, 265 (46.2%) had died before November 2006. Of the
remaining 308 patients, 20 (6.5%) could not be invited to
the follow-up examination because they had emigrated or
their address was unknown. Of the remaining patients, 201
(65.3%) participated in the follow-up examination and 87
patients (28.2%) refused to take part (Fig. 1). The
participants’ characteristics at the baseline examination are
presented in Table 1. Patients who died before the follow-
up examination were older, had a longer duration of
diabetes, and were more likely to have proteinuria, a
history of smoking, a higher systolic blood pressure, a
higher level of retinopathy and a higher rate of maculopathy
than patients who were still alive. The proportion of women
was higher among those who chose not to participate than
among the deceased and the follow-up participants.
Mean age and duration of diabetes at follow-up were
58.9 and 44 years, respectively (Table 2). Some sex-specific
differences were found. A higher rate of men had a history
of smoking and the diastolic blood pressure was also higher
in men. As in the general population [13], women had a
higher level of total cholesterol and HDL-cholesterol. At
follow-up, the level of retinopathy was graded in all
patients (Table 3). No retinopathy was found in six patients
(3.0%), non-proliferative retinopathy occurred in 92
patients (45.8%), and 103 patients (52.9%) had proliferative
retinopathy. There were no differences between men and
women.
In follow-up participants (n=201), 33 already had
proliferative retinopathy at baseline. Consequently 168
were at risk of developing proliferative retinopathy during
follow-up. Of these, 60 had no retinopathy and 108 had
non-proliferative retinopathy at baseline. The 25 year
incidence of proliferative retinopathy was 42.9% for all
patients at risk and was significantly higher among patients
who had already non-proliferative retinopathy at baseline
compared with patients without retinopathy (52.8% vs
25.0%, p<0.001).
A logistic regression was performed to identify risk
factors for incident proliferative retinopathy (Table 4). In a
multiple regression, baseline HbA1 (OR 2.14 per 1%
increase, 95% CI 1.06–4.31) and non-proliferative retinop-
athy (OR 4.61, 95% CI 1.94–11.0) were the only risk
factors identified. Duration of diabetes, proteinuria, smok-
ing, systolic and diastolic blood pressure, BMI and
maculopathy were not statistically significantly associated
with development of proliferative retinopathy in the age-
and sex-adjusted or the multivariate model.
Discussion
A large population-based cohort of Danish type 1 diabetic
patients was followed for 25 years. Diabetic retinopathy
was prevalent in long-term survivors, occurring in almost
all patients; the cumulative incidence of proliferative
retinopathy was 42.9%. Hyperglycaemia and non-
proliferative diabetic retinopathy at baseline were identified
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as predictors of incident proliferative retinopathy whereas
other markers such as blood pressure, proteinuria, smoking
and maculopathy were not.
The 25 year cumulative incidence of proliferative
retinopathy was similar to the 42% figure found in the
WESDR population [5]. A high long-term incidence of
proliferative retinopathy has been confirmed in other
studies [14–16]. However, in a Norwegian cohort Skrivar-
haug et al. reports a 25 year cumulative incidence of
proliferative retinopathy of only 10.9% [17]. Given the
ethnic similarities between the Norwegian group and our
patients from Denmark, the difference is striking. It may,
however, be explained by a variety of factors. First,
baseline age and duration of diabetes was higher in our
group. Second, in the Norwegian study only one retinal
image was obtained for each eye and grading was not done
at a grading centre. In the Norwegian cohort, the incidence
of non-proliferative retinopathy equalled the 10% incidence
of proliferative retinopathy. Given the limitations above,
proliferative retinopathy may have been misclassified in
Characteristic Overall (n=201) Men (n=120) Women (n=81) p value
Age (years) 58.9±10.1 58.4±9.7 59.6±10.7 0.43
Duration of diabetes (years) 44±8 44±7 45±8 0.17
History of smoking (%) 59.7 68.6 46.3 0.002
Neuropathy (%) 52.7 57.9 45.0 0.07
Macrovascular disease (%) 21.9 24.8 17.5 0.22
HbA1c (%) 7.7±1.1 7.7±1.1 7.7±1.0 0.83
Nephropathy (%) 0.82
Normoalbuminuria 66.8 65.8 68.4
Microalbuminuria 22.6 22.5 22.8
Macroalbuminuria 10.6 11.7 8.9
Blood-pressure-lowering treatment (%) 62.0 66.1 55.7 0.14
Systolic blood pressure (mmHg) 149±21 151±20 146±22 0.10
Diastolic blood pressure (mmHg) 76±10 77±10 73±10 0.01
Lipid-lowering treatment (%) 47.2 44.2 51.9 0.29
Lipids
Total cholesterol (mmol/l) 4.8±0.9 4.7±0.8 5.0±0.9 0.01
HDL-cholesterol (mmol/l) 2.1±0.6 1.9±0.6 2.3±0.6 <0.001
LDL-cholesterol (mmol/l) 2.4±0.7 2.4±0.7 2.4±0.7 0.98
Triacylglycerol (mmol/l) 1.1±0.6 1.1±0.6 1.0±0.6 0.07
Table 2 Overall and sex-specific
characteristics of patients at
follow-up
Continuous data are presented as
means with standard deviations;
categorical data are presented as
percentages
Table 1 Baseline characteristics (1981–1982) of patients according to status at follow-up (2007–2008)
Characteristic Dead (n=265) Non-participants (n=87) Participants (n=201) p value
Sex (% male) 58.5 43.7 60.2 0.03
Age (years) 45.9±12.6 32.1±10.5 33.0±10.1 <0.001
Duration of diabetes (years) 28±12 18±8 18±8 <0.001
HbA1 (%) 8.5±1.1 8.7±0.7 8.6±0.7 0.60
Proteinuria (%) 21.8 5.0 4.6 <0.001
History of smoking (%) 78.5 51.7 57.2 <0.001
Systolic BP (mmHg) 155±25 141±22 142±21 <0.001
Diastolic BP (mmHg) 95±14 93±14 92±12 0.26
BMI (kg/m2) 22.7±3.1 22.3±2.4 22.3±2.5 0.63
Level of retinopathy (%) <0.001
None 18.1 33.3 29.9
Non-proliferative 46.0 54.0 53.7
Proliferative 35.9 12.6 16.4
Maculopathy (%) 29.1 9.2 12.9 <0.001
Continuous data are presented as means with standard deviations; categorical data are presented as percentages
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some patients and, subsequently, the incidence of prolifer-
ative retinopathy may have been underestimated.
Proliferative diabetic retinopathy is the leading cause of
blindness in type 1 diabetes [3, 18], but it has also been
associated with non-ocular complications such as heart
attack, stroke, nephropathy, amputations and mortality [3,
19–21]. In an age- and sex-adjusted model of 16 year
follow-up of type 1 diabetic WESDR patients, Klein and
associates found an all-cause mortality hazard ratio of 5.53
(95% CI 3.06–9.99) for patients with proliferative retinop-
athy at baseline [19]. In a recent publication we were able
to expand this finding by demonstrating that mortality
depended upon proliferative retinopathy as well as protein-
uria [21]. The 25 year survival rate was significantly lower
(p<0.001) for patients who had both (16.7%) as compared
with patients with: neither (66.4%); proliferative retinopa-
thy only (48.2%); or proteinuria only (33.3%).
In our study, non-proliferative retinopathy was identified
as a major risk factor for incident proliferative retinopathy.
Patients with baseline non-proliferative retinopathy were
five times more likely to develop proliferative retinopathy
than patients without. This is not surprising given the
natural history of proliferative retinopathy. In the WESDR,
there was a significant trend of progression to proliferative
retinopathy with increasing baseline level of retinopathy
[8]. For patients with moderate non-proliferative retino-
pathy in both eyes (ETDRS level 41), the 4 year progres-
sion to proliferative retinopathy was 42.4%.
We identified glycaemic regulation as an important
predictor of proliferative retinopathy. The OR for incident
ETDRS level Overall (n=201) Men (n=121) Women (n=80)
% n % n % n
No retinopathy 3.0 6 2.5 3 3.8 3
10 3.0 6 2.5 3 3.8 3
Non-proliferative retinopathy 45.8 92 44.7 54 47.8 38
20 13.9 28 15.7 19 11.3 9
31 12.4 25 9.9 12 16.3 13
37 7.5 15 7.4 9 7.5 6
43 10.5 21 9.9 12 11.3 9
47 1.5 3 1.7 2 1.3 1
Proliferative retinopathy 51.2 103 52.9 64 48.8 39
60 8.0 16 9.1 11 6.3 5
62 2.0 4 2.5 3 1.3 1
63 8.5 17 8.3 10 8.8 7
64 4.5 9 5.8 7 2.5 2
65 19.4 39 18.2 22 21.3 17
71 4.0 8 5.0 6 2.5 2
85 5.0 10 4.1 5 6.3 5
Table 3 Overall and sex-specific
level of retinopathy in the worst
eye at follow-up
Table 4 Logistic regression indicating ORs for 25 year progression to proliferative retinopathy according to baseline risk factors in age- and sex-
adjusted and multivariate models
Risk factor Increment Age- and sex-adjusted model OR (95% CI) Multivariate model OR (95% CI)
Duration 10 years 1.02 (0.59–1.78) 0.69 (0.35–1.36)
HbA1 1% 1.71 (0.95–3.08) 2.14 (1.06–4.31)*
Proteinuria vs no proteinuria 6.82 (0.73–64.1) 5.17 (0.49–54.3)
History of smoking vs never smoked 1.34 (0.71–2.53) 1.37 (0.64–2.91)
Systolic BP 10 mmHg 1.06 (0.89–1.26) 0.91 (0.69–1.20)
Diastolic BP 10 mmHg 1.16 (0.89–1.51) 1.31 (0.86–1.99)
BMI 1 kg/m2 1.09 (0.95–1.24) 1.01 (0.86–1.20)
Non-proliferative retinopathy vs no retinopathy 4.83 (2.21–10.5)* 4.61 (1.94–11.0)*
Maculopathy vs no maculopathy 5.71 (0.62–52.3) 5.61 (0.54–58.5)
*p<0.05
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proliferative retinopathy at the 25 year follow-up examina-
tion was 2.14 (95% CI 1.06–4.31) for each 1% increase in
baseline HbA1. Thus, given similarities in other risk factors,
the risk of proliferative retinopathy was 9.8 times higher for
a patient who had a baseline HbA1 of 10.0% than for a
patient with HbA1 7.0%. The effect of hyperglycaemia on
incident proliferative retinopathy is well known from other
long-term studies of type 1 diabetes [5, 17]. Furthermore, in
the Diabetes Control and Complications Trial the benefits
of strict glycaemic regulation were demonstrated in type 1
diabetes [22]. Progression to severe non-proliferative
retinopathy or proliferative retinopathy was reduced by
47% among intensively treated patients (p=0.01).
Only 3% of our patients had no signs of retinopathy at
follow-up. This is in accordance with the very high rate of
diabetic retinopathy found at the baseline examination in
the WESDR study in 1984 [1]. Diabetic retinopathy was
present in 97.5% of all patients who had had diabetes for
longer than 15 years. The similarity of these results is
interesting given that 23 years have passed. A lower
prevalence of retinopathy in our study would have been
expected.
Other possible risk factors for incident proliferative
retinopathy were examined. In the multivariate analysis,
proliferative retinopathy could not be predicted by duration
of diabetes, proteinuria, smoking, blood pressure (systolic
and diastolic), BMI or maculopathy. Results from other
long-term follow-up studies are conflicting. Skrivarhaug et
al. confirmed that proliferative retinopathy was independent
of duration of diabetes, smoking and blood pressure [17]. In
the 25 year follow-up of the WESDR cohort, however,
proliferative retinopathy was predicted by baseline protein-
uria, systolic blood pressure and BMI but remained
unrelated to diastolic blood pressure and smoking [5]. In
the EURODIAB Prospective Complications Study, risk
factors for proliferative retinopathy were examined in a
7 year follow-up [23]. In EURODIAB, glycaemic regula-
tion and baseline retinopathy were confirmed as risk factors
for incident proliferative retinopathy, as was albumin
excretion rate.
Fortunately, recent studies indicate that the incidence of
proliferative retinopathy is decreasing in type 1 diabetes [15,
16, 24]. In a Danish study, the 20 year cumulative incidence
of proliferative retinopathy was 31.2% in patients diagnosed
in 1965–1969, compared with 12.5% in patients diagnosed
in 1979–1984 [24]. The huge improvements in diabetes care
with better control of blood glucose (i.e. with home
monitoring and designer insulin formulations) and blood
pressure are the most likely reasons for this improvement.
The major strengths of this study are the population-
based design and the long follow-up period. In many
studies, incidence rates are overestimated because of
referral bias. Studies which only include patients referred
to specialist units may not be representative of the entire
group of interest. Looking at complications in patients with
a median duration of diabetes of 43 years makes it possible
to evaluate the long-term impact of the disease more
accurately.
Limitations must be considered. First, survival bias is a
major concern. Patients who participated at the follow-up
examination had all survived more than 30 years of
diabetes. Many risk factors of interest have been associated
with mortality [20], as has proliferative retinopathy [19,
21]. This may attenuate the association of proliferative
retinopathy and risk factors such as blood pressure,
proteinuria, smoking, BMI and maculopathy. Second, at
the baseline examination the level of retinopathy was
evaluated from ophthalmoscopy as fundus photographs
were not available. If imaging had been on hand, the
retinopathy grading would have been more accurate and
adjustments for different levels of non-proliferative reti-
nopathy would have been possible. Finally, our study is
also limited by the lack of data on lipids and blood-
pressure-lowering therapy at baseline as well as intermedi-
ary risk-factor and endpoint assessments during the long
follow-up period.
To conclude, diabetic retinopathy is almost universal in
long-surviving type 1 diabetic patients. Glycaemic regula-
tion and non-proliferative retinopathy are important risk
factors for proliferative retinopathy. Good glycaemic
control is crucial and attending regular eye examinations
may reduce the burden of visual impairment in type 1
diabetes.
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